vs

Side-by-side financial comparison of Rubrik, Inc. (RBRK) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $350.2M, roughly 1.8× Rubrik, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs -18.2%, a 52.7% gap on every dollar of revenue. On growth, Rubrik, Inc. posted the faster year-over-year revenue change (48.3% vs 4.8%).

Rubrik, Inc. is an American cloud data management and data security company based in Palo Alto, California, founded in January 2014. The company is listed on the New York Stock Exchange after going public in April 2024.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

RBRK vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.8× larger
RPRX
$622.0M
$350.2M
RBRK
Growing faster (revenue YoY)
RBRK
RBRK
+43.5% gap
RBRK
48.3%
4.8%
RPRX
Higher net margin
RPRX
RPRX
52.7% more per $
RPRX
34.4%
-18.2%
RBRK

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
RBRK
RBRK
RPRX
RPRX
Revenue
$350.2M
$622.0M
Net Profit
$-63.8M
$214.2M
Gross Margin
80.5%
Operating Margin
-21.6%
62.4%
Net Margin
-18.2%
34.4%
Revenue YoY
48.3%
4.8%
Net Profit YoY
51.2%
2.9%
EPS (diluted)
$-0.32
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RBRK
RBRK
RPRX
RPRX
Q4 25
$350.2M
$622.0M
Q3 25
$309.9M
$609.3M
Q2 25
$278.5M
$578.7M
Q1 25
$258.1M
$568.2M
Q4 24
$236.2M
$593.6M
Q3 24
$205.0M
$564.7M
Q2 24
$187.3M
$537.3M
Q1 24
$568.0M
Net Profit
RBRK
RBRK
RPRX
RPRX
Q4 25
$-63.8M
$214.2M
Q3 25
$-95.9M
$288.2M
Q2 25
$-102.1M
$30.2M
Q1 25
$-114.9M
$238.3M
Q4 24
$-130.9M
$208.2M
Q3 24
$-176.9M
$544.0M
Q2 24
$-732.1M
$102.0M
Q1 24
$4.8M
Gross Margin
RBRK
RBRK
RPRX
RPRX
Q4 25
80.5%
Q3 25
79.5%
Q2 25
78.3%
Q1 25
77.4%
Q4 24
76.2%
Q3 24
73.1%
Q2 24
48.8%
Q1 24
Operating Margin
RBRK
RBRK
RPRX
RPRX
Q4 25
-21.6%
62.4%
Q3 25
-30.5%
70.1%
Q2 25
-33.4%
36.3%
Q1 25
-45.0%
94.0%
Q4 24
-52.8%
60.9%
Q3 24
-82.1%
Q2 24
-387.0%
50.2%
Q1 24
-13.0%
Net Margin
RBRK
RBRK
RPRX
RPRX
Q4 25
-18.2%
34.4%
Q3 25
-31.0%
47.3%
Q2 25
-36.7%
5.2%
Q1 25
-44.5%
41.9%
Q4 24
-55.4%
35.1%
Q3 24
-86.3%
96.3%
Q2 24
-390.8%
19.0%
Q1 24
0.8%
EPS (diluted)
RBRK
RBRK
RPRX
RPRX
Q4 25
$-0.32
$0.49
Q3 25
$-0.49
$0.67
Q2 25
$-0.53
$0.07
Q1 25
$5.69
$0.55
Q4 24
$-0.71
$0.46
Q3 24
$-0.98
$1.21
Q2 24
$-11.48
$0.23
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RBRK
RBRK
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$307.1M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$-524.4M
$9.7B
Total Assets
$2.5B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RBRK
RBRK
RPRX
RPRX
Q4 25
$307.1M
$618.7M
Q3 25
$322.7M
$938.9M
Q2 25
$284.0M
$631.9M
Q1 25
$186.3M
$1.1B
Q4 24
$103.9M
$929.0M
Q3 24
$142.3M
$950.1M
Q2 24
$502.6M
$1.8B
Q1 24
$843.0M
Total Debt
RBRK
RBRK
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
RBRK
RBRK
RPRX
RPRX
Q4 25
$-524.4M
$9.7B
Q3 25
$-564.3M
$9.6B
Q2 25
$-556.5M
$9.5B
Q1 25
$-553.7M
$9.8B
Q4 24
$-521.1M
$10.3B
Q3 24
$-499.3M
$10.3B
Q2 24
$-514.6M
$9.8B
Q1 24
$9.9B
Total Assets
RBRK
RBRK
RPRX
RPRX
Q4 25
$2.5B
$19.6B
Q3 25
$2.4B
$19.3B
Q2 25
$1.5B
$18.3B
Q1 25
$1.4B
$17.6B
Q4 24
$1.3B
$18.2B
Q3 24
$1.2B
$18.0B
Q2 24
$1.2B
$17.7B
Q1 24
$16.1B
Debt / Equity
RBRK
RBRK
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RBRK
RBRK
RPRX
RPRX
Operating Cash FlowLast quarter
$85.5M
$827.1M
Free Cash FlowOCF − Capex
$80.7M
FCF MarginFCF / Revenue
23.1%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters
$256.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RBRK
RBRK
RPRX
RPRX
Q4 25
$85.5M
$827.1M
Q3 25
$64.7M
$702.6M
Q2 25
$39.7M
$364.0M
Q1 25
$83.6M
$596.1M
Q4 24
$23.1M
$742.5M
Q3 24
$-27.1M
$703.6M
Q2 24
$-31.4M
$658.2M
Q1 24
$664.6M
Free Cash Flow
RBRK
RBRK
RPRX
RPRX
Q4 25
$80.7M
Q3 25
$61.2M
Q2 25
$36.8M
Q1 25
$78.0M
Q4 24
$18.0M
Q3 24
$-29.7M
Q2 24
$-35.0M
Q1 24
FCF Margin
RBRK
RBRK
RPRX
RPRX
Q4 25
23.1%
Q3 25
19.8%
Q2 25
13.2%
Q1 25
30.2%
Q4 24
7.6%
Q3 24
-14.5%
Q2 24
-18.7%
Q1 24
Capex Intensity
RBRK
RBRK
RPRX
RPRX
Q4 25
1.4%
Q3 25
1.1%
Q2 25
1.0%
Q1 25
2.2%
Q4 24
2.1%
Q3 24
1.3%
Q2 24
1.9%
Q1 24
Cash Conversion
RBRK
RBRK
RPRX
RPRX
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
2.50×
Q4 24
3.57×
Q3 24
1.29×
Q2 24
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RBRK
RBRK

Subscription And Circulation$336.4M96%
Other$12.3M4%
Software And Services$4.9M1%
Maintenance$1.5M0%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons